Your session is about to expire
← Back to Search
Neuraminidase Inhibitor
Zanamivir for Type 2 Diabetes (NAED Trial)
Phase 2
Waitlist Available
Led By Luis Martinez-Lemus, PhD
Research Sponsored by University of Missouri-Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of T2D classified based on physician diagnosis
Men and women with a BMI of 25-39 kg/m2
Must not have
Hormone replacement therapy
Immunosuppressant therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 and 5 days
Awards & highlights
Summary
This trial is testing whether the drug zanamivir can help improve the function of blood vessels in people with type 2 diabetes.
Who is the study for?
This trial is for adults aged 45-64 with Type 2 Diabetes, a BMI of 25-39 kg/m2, and no severe health issues like active cancer or heart disease. It's not for pregnant women, smokers, those with allergies to lactose or milk proteins, heavy drinkers, or people on certain medications.
What is being tested?
The study tests if Zanamivir can improve blood vessel function in Type 2 Diabetes patients. Participants will receive Zanamivir to see if it helps their condition by inhibiting neuraminidase activity.
What are the potential side effects?
Zanamivir may cause side effects such as headaches, nausea, diarrhea, bronchitis-like symptoms (coughing and trouble breathing), ear/nose/throat infections; however specific risks related to this trial are not detailed.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with type 2 diabetes by a doctor.
Select...
My BMI is between 25 and 39.
Select...
I am between 45 and 64 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am on hormone replacement therapy.
Select...
I am currently on immunosuppressant therapy.
Select...
I have a long-term kidney or liver disease.
Select...
My cancer is currently active.
Select...
I have a history of heart disease, including heart attack or stroke.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0 and 5 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 and 5 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in glycocalyx integrity
Secondary study objectives
Change in Vascular function
Side effects data
From 2009 Phase 3 trial • 64 Patients • NCT0078478410%
pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Influenza Vaccine
Antiviral Prophylaxis
Trial Design
1Treatment groups
Experimental Treatment
Group I: Zanamivir treatmentExperimental Treatment1 Intervention
Study participants will receive 5 days of treatment with a zanamivir inhaler.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Zanamivir
2009
Completed Phase 3
~1050
Find a Location
Who is running the clinical trial?
University of Missouri-ColumbiaLead Sponsor
376 Previous Clinical Trials
628,647 Total Patients Enrolled
Luis Martinez-Lemus, PhDPrincipal InvestigatorUniversity of Missouri, School of Medicine
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a history of asthma or chronic lung disease.I am on hormone replacement therapy.I am currently on immunosuppressant therapy.I have been diagnosed with type 2 diabetes by a doctor.You have had an allergic reaction to lactose or milk proteins in the past.My BMI is between 25 and 39.You drink more than 14 drinks a week if you're a man, or more than 7 drinks a week if you're a woman.I have a long-term kidney or liver disease.I have not received a nasal flu vaccine within 2 weeks before or plan to within 48 hours after taking zanamivir.You currently smoke or use tobacco products.My cancer is currently active.You have an autoimmune disease.I am between 45 and 64 years old.I have a history of heart disease, including heart attack or stroke.
Research Study Groups:
This trial has the following groups:- Group 1: Zanamivir treatment
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger